Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor Resources
Investor News
Share Price / Index
May 19, 2026
Not intended for U.S. and UK Media
New drug applications for Bayer’s FXIa inhibitor accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare
May 12, 2026
First quarter of 2026:
Bayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026
May 06, 2026
Not intended for UK Media
Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline
Discover More
